BACKGROUND: Sexually Transmitted Infections (STIs) have been shown to enhance the transmission of the Human Immunodeficiency Virus (HIV). The Hepatitis B and the Hepatitis C viral infections are highly prevalent among the HIV-infected persons as a result of shared transmission routes. AIM: To determine the seroprevalence of the HIV, Syphilis, HBV and HCV infections and their co-infection rates among Female Sex Workers (FSWs). SETTINGS AND DESIGN: 250 blood samples were collected from FSWs from a red light area of Mumbai by using an outreach strategy. MATERIALS AND METHODS: Their sera were tested for the HIV antibodies as per the strategy II of the NACO guidelines, for syphilis by RPR, for the HCV antibodies and for HBsAg by ELISA. RESULTS: The study group showed (105/250) 42% HIV reactivity, (15/250) 6% RPR reactivity, (20/250) 8% HBsAg positivity, (7/250) 2.8% HCV reactivity, (11/250) 4.4% HIV-RPR reactivity, (7/250) 2.8% HIV-HBV co-infection and (3/250)1.2% HIV-HCV co-infection. Statistical test which was used: The Chi square test. CONCLUSION: A high HIV sero-prevalence was found among the FSWs. A high HIV prevalence was found among the RPR reactive FSWs. The relationship between the HIV reactivity and the RPR reactivity was statistically significant. Co-infections with HBV and HCV were detected among the HIV reactive FSWs, but they were not statistically significant.
BACKGROUND: Sexually Transmitted Infections (STIs) have been shown to enhance the transmission of the Human Immunodeficiency Virus (HIV). The Hepatitis B and the Hepatitis C viral infections are highly prevalent among the HIV-infectedpersons as a result of shared transmission routes. AIM: To determine the seroprevalence of the HIV, Syphilis, HBV and HCV infections and their co-infection rates among Female Sex Workers (FSWs). SETTINGS AND DESIGN: 250 blood samples were collected from FSWs from a red light area of Mumbai by using an outreach strategy. MATERIALS AND METHODS: Their sera were tested for the HIV antibodies as per the strategy II of the NACO guidelines, for syphilis by RPR, for the HCV antibodies and for HBsAg by ELISA. RESULTS: The study group showed (105/250) 42% HIV reactivity, (15/250) 6% RPR reactivity, (20/250) 8% HBsAg positivity, (7/250) 2.8% HCV reactivity, (11/250) 4.4% HIV-RPR reactivity, (7/250) 2.8% HIV-HBV co-infection and (3/250)1.2% HIV-HCV co-infection. Statistical test which was used: The Chi square test. CONCLUSION: A high HIV sero-prevalence was found among the FSWs. A high HIV prevalence was found among the RPR reactive FSWs. The relationship between the HIV reactivity and the RPR reactivity was statistically significant. Co-infections with HBV and HCV were detected among the HIV reactive FSWs, but they were not statistically significant.
Authors: Maite Gutiérrez; Pilar Tajada; Amparo Alvarez; Rosa De Julián; Margarita Baquero; Vincent Soriano; Africa Holguín Journal: J Med Virol Date: 2004-12 Impact factor: 2.327
Authors: J C Forbi; N Onyemauwa; S D Gyar; A O Oyeleye; P Entonu; S M Agwale Journal: Rev Inst Med Trop Sao Paulo Date: 2008 Jul-Aug Impact factor: 1.846
Authors: María A Pando; Carolina Berini; Mariel Bibini; Mauro Fernández; Elena Reinaga; Sergio Maulen; Rubén Marone; Mirna Biglione; Silvia M Montano; Christian T Bautista; Mercedes Weissenbacher; José L Sanchez; María M Avila Journal: Am J Trop Med Hyg Date: 2006-02 Impact factor: 2.345
Authors: Nimisha D Shethwala; Summaiya A Mulla; J K Kosambiya; Vikas K Desai Journal: Indian J Pathol Microbiol Date: 2009 Apr-Jun Impact factor: 0.740
Authors: Monica Alonso; Annika Gutzman; Rafael Mazin; Carlos E Pinzon; Ludovic Reveiz; Massimo Ghidinelli Journal: Int J Public Health Date: 2015-08-23 Impact factor: 3.380
Authors: Fabien Roch Niama; Nadia Claricelle Loukabou Bongolo; Pembe Issamou Mayengue; Franck Fortuné Mboussou; Edith Sophie Kombo Bayonne; Florian Michael Kouckodila Nzingoula; Louis Regis Dossou-Yovo; Igor Louzolo; Mandingha Kosso Etoka-Beka; Achile Lanzy; Irène Yameogo; Davy Louvouezo; Simon Charles Kobawila; Marie-Francke Puruhence; Henri Joseph Parra Journal: Arch Public Health Date: 2017-05-08